i had a similar plan slumdawg. I did unload my shares last week, but this is a tough loss. shorts and option sellers win again
good to see all the old timers. Had been watching for an entry, hopefully i timed it right was glad to get the cc out of the way first . nice cash position, but the burn rate will increase. blum loves to spend that cash lol im not much of a message board guy any more. most are totally out of control. good luck!
nice pullback. BUY! BUY! BUY! LOL back in for a run up. prob wont hold through I am shooting for results around september ish.
LOL offshore. glad to see you guys are still holding things down around here. no position at the moment. I would like to get back in for the ome run up at least. that gap in the chart looks juicy
yep, it did surprise me how low it went. i think we move back to 3 in a few days. killed the runup though gonna have to re evaluate how to play this..
you heard the man. isonep trial done in "mid april" add around 6 weeks for results. puts us at last week in may/first week in june. guess now we have something to trade against.
the smoke will clear soon enough. although the asonep results are disappointing, this investment has always been about isonep for me. looks like the after hours headline traders are about done. i picked up a few shares don't really know why other than i thought they were cheep
Great point John. I would hope that they would crank it back up when the price and volume is/are much higher, but who knows with this group. How much of the ATM is still left?
i am thinking april. then the usual 6 weeks for public data. great point about the follow up data. the second half of the year will be full of news for us. its been such a long journey for many of us...
another shot across the bow from novartis at regeneron. alcon compound RTH258 beats eylea in a head to head phase 2.
'Phase II study met primary endpoint, demonstrating promising visual acuity gains in patients with neovascular (wet) age-related macular degeneration
Data shows the potential for less frequent dosing and reduced treatment burden with RTH258 compared to aflibercept
Phase III clinical trial program initiated in December 2014, with 1700 patients expected to be enrolled in more than 50 countries'
Cant wait to see the isonep results in the combo arms.